Physician profile
Thaddeus G Sutton
NPI 1558321349
$5,528.84
in general payments reported to CMS, 2019-2025
33 companies · $952 in 2025
The $952 reported for 2025 was more than what 84% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,451 · 2020: $363 · 2021: $332 · 2022: $136 · 2023: $1,134 · 2024: $1,160 · 2025: $952.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,246.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,246.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $834.30 | 2019-2025 | Repatha, Otezla, Repatha |
| Lilly USA, LLC | $794.98 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Novo Nordisk INC | $743.68 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $675.38 | 2019-2025 | Jardiance |
| Abbvie INC. | $396.68 | 2022-2025 | Ubrelvy, Vraylar, Qulipta |
| Shield Therapeutics INC | $386.19 | 2023-2025 | Accrufer |
| Novartis Pharmaceuticals Corporation | $210.09 | 2019-2024 | |
| Astrazeneca Pharmaceuticals Lp | $185.50 | 2019-2025 | Airsupra, Fasenra |
| Janssen Pharmaceuticals, INC | $177.51 | 2019 | |
| Glaxosmithkline, LLC. | $134.51 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbott Laboratories | $130.12 | 2022-2024 | Freestyle Libre 3 |
| Amarin Pharma, INC. | $108.02 | 2019 | |
| Dexcom, INC. | $107.66 | 2021-2024 | Dexcom G6 Transmitter |
| Pfizer INC. | $94.75 | 2020-2024 | |
| Exact Sciences Corporation | $70.42 | 2023-2024 | Cologuard Collection Kit |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $61.73 | 2019-2020 | |
| Biohaven Pharmaceuticals, INC. | $60.59 | 2021 | |
| Astellas Pharma US INC | $58.77 | 2023-2024 | Veozah |
| Insulet Corporation | $34.82 | 2021-2024 | Omnipod |
| Kowa Pharmaceuticals America, INC. | $29.43 | 2020 | |
| Sanofi Pasteur INC. | $23.60 | 2019 | |
| Xeris Pharmaceuticals, INC. | $22.09 | 2024 | Gvoke Hypopen |
| Lifescan, INC. | $21.69 | 2023 | |
| Phadia US INC. | $19.73 | 2024 | Immunocap |
| Sanofi-Aventis U.S. LLC | $19.55 | 2019 | |
| Philips North America LLC | $17.80 | 2024 | (Ck6) Holter |
| Hikma Pharmaceuticals USA | $17.63 | 2019 | |
| Abiomed | $17.39 | 2024 | Impella |
| Teva Pharmaceuticals USA, INC. | $17.36 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.81 | 2019 | |
| Cashflow Solutions, LLC | $14.77 | 2023 | Pcd-51 731a (US) - White, Lympha Press Optimal Plus(US) Bt, Pcd-52 737a (US) White |
| Mylan Specialty L.P. | $13.75 | 2023 | Yupelri |
| Allergan, INC. | $13.54 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thaddeus Sutton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.